The Korean Journal of Physiology and Pharmacology

The Korean Society of Pharmacology (대한약리학회)
권호 표지
DOI QR코드

DOI QR Code

Long Term Effect of High Glucose and Phosphate Levels on the OPG/RANK/RANKL/TRAIL System in the Progression of Vascular Calcification in rat Aortic Smooth Muscle Cells

  • Kang, Yang Ho (Division of Endocrinology and Metabolism, Department of Internal Medicine, Pusan National University School of Medicine) ;
  • Jin, Jung Sook (Research Institute for Convergence of Biomedical Science and Technology) ;
  • Son, Seok Man (Division of Endocrinology and Metabolism, Department of Internal Medicine, Pusan National University School of Medicine)
  • Received : 2014.10.20
  • Accepted : 2014.12.17
  • Published : 2015.03.30
Download PDF
⟨ Previous Next ⟩

Abstract

Osteoprotegerin (OPG), receptor activator of NF-${\kappa}B$ ligand (RANKL)/receptor activator of NF-${\kappa}B$ (RANK) axis, and TNF-related apoptosis-inducing ligand (TRAIL) participate in vascular calcification process including atherosclerosis, but their contributions under high glucose (HG) and phosphate (HP) condition for a long-term period (more than 2 weeks) have not been fully determined. In this study, we evaluated the effects of HG and HP levels over 2 or 4 weeks on the progression of vascular calcification in rat vascular smooth muscle cells (VSMCs). Calcium deposition in VSMCs was increased in medium containing HG (30 mmol/L D-glucose) with ${\beta}$-glycerophosphate (${\beta}$-GP, 12 mmol/L) after 2 weeks and increased further after 4 weeks. OPG mRNA and protein expressions were unchanged in HG group with or without ${\beta}$-GP after 2 weeks. However, after 4 weeks, OPG mRNA and protein expressions were significantly lower in HG group with ${\beta}$-GP. No significant expression changes were observed in RANKL, RANK, or TRAIL during the experiment. After 4 weeks of treatment in HG group containing ${\beta}$-GP and rhBMP-7, an inhibitor of vascular calcification, OPG expressions were maintained. Furthermore, mRNA expression of alkaline phosphatase (ALP), a marker of vascular mineralization, was lower in the presence of rhBMP-7. These results suggest that low OPG levels after long term HG and phosphate stimulation might reduce the binding of OPG to RANKL and TRAIL, and these changes could increase osteo-inductive VSMC differentiation, especially vascular mineralization reflected by increased ALP activity during vascular calcification.

Keywords

References

  1. Johnson RC Leopold JA, Loscalzo J. Vascular calcification: pathobiological mechanisms and clinical implications. Circ Res. 2006;99:1044-1059. https://doi.org/10.1161/01.RES.0000249379.55535.21
  2. Shioi A, Nishizawa Y, Jono S, Koyama H, Hosoi M, Morii H. Beta-glycerophosphate accelerates calcification in cultured bovine vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1995;15:2003-2009. https://doi.org/10.1161/01.ATV.15.11.2003
  3. Steitz SA, Speer MY, Curinga G, Yang HY, Haynes P, Aebersold R, Schinke T, Karsenty G, Giachelli CM. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res. 2001;89:1147-1154. https://doi.org/10.1161/hh2401.101070
  4. Chen NX, O'Neill KD, Duan D, Moe SM. Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells. Kidney Int. 2002;62:1724-1731. https://doi.org/10.1046/j.1523-1755.2002.00625.x
  5. Lehto S, Niskanen L, Suhonen M, Ronnemaa T, Laakso M. Medial artery calcification. A neglected harbinger of cardiovascular complications in non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol. 1996;16:978-983. https://doi.org/10.1161/01.ATV.16.8.978
  6. Chen NX, Moe SM. Arterial calcification in diabetes. Curr Diab Rep. 2003;3:28-32. https://doi.org/10.1007/s11892-003-0049-2
  7. Vattikuti R, Towler DA. Osteogenic regulation of vascular calcification: an early perspective. Am J Physiol Endocrinol Metab. 2004;286:E686-696. https://doi.org/10.1152/ajpendo.00552.2003
  8. Chen NX, Duan D, O'Neill KD, Moe SM. High glucose increases the expression of Cbfa1 and BMP-2 and enhances the calcification of vascular smooth muscle cells. Nephrol Dial Transplant. 2006;21:3435-3442. https://doi.org/10.1093/ndt/gfl429
  9. American Diabetes Association. Standards of medical care in diabetes--2014. Diabetes Care. 2014;37 Suppl 1:S14-80. https://doi.org/10.2337/dc14-S014
  10. Singh VP, Bali A, Singh N, Jaggi AS. Advanced glycation end products and diabetic complications. Korean J Physiol Pharmacol. 2014;18:1-14. https://doi.org/10.4196/kjpp.2014.18.1.1
  11. Everhart JE, Pettitt DJ, Knowler WC, Rose FA, Bennett PH. Medial arterial calcification and its association with mortality and complications of diabetes. Diabetologia. 1988;31:16-23.
  12. Van Campenhout A, Golledge J. Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis. 2009;204: 321-329. https://doi.org/10.1016/j.atherosclerosis.2008.09.033
  13. Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res. 2004;95:1046-1057. https://doi.org/10.1161/01.RES.0000149165.99974.12
  14. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, Dodds RA, James IE, Rosenberg M, Lee JC, Young PR. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem. 1998;273:14363-14367. https://doi.org/10.1074/jbc.273.23.14363
  15. Gochuico BR, Zhang J, Ma BY, Marshak-Rothstein A, Fine A. TRAIL expression in vascular smooth muscle. Am J Physiol Lung Cell Mol Physiol. 2000;278:L1045-1050. https://doi.org/10.1152/ajplung.2000.278.5.L1045
  16. Kiechl S, Werner P, Knoflach M, Furtner M, Willeit J, Schett G. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease. Expert Rev Cardiovasc Ther. 2006;4:801-811. https://doi.org/10.1586/14779072.4.6.801
  17. Toffoli B, Pickering RJ, Tsorotes D, Wang B, Bernardi S, Kantharidis P, Fabris B, Zauli G, Secchiero P, Thomas MC. Osteoprotegerin promotes vascular fibrosis via a TGF- 1 autocrine loop. Atherosclerosis. 2011;218:61-68. https://doi.org/10.1016/j.atherosclerosis.2011.05.019
  18. Candido R, Toffoli B, Corallini F, Bernardi S, Zella D, Voltan R, Grill V, Celeghini C, Fabris B. Human full-length osteoprotegerin induces the proliferation of rodent vascular smooth muscle cells both in vitro and in vivo. J Vasc Res. 2010;47: 252-261. https://doi.org/10.1159/000257339
  19. Olesen P, Ledet T, Rasmussen LM. Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-alpha. Diabetologia. 2005;48:561-568. https://doi.org/10.1007/s00125-004-1652-8
  20. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/ RANKL/RANK system for bone and vascular diseases. JAMA. 2004;292:490-495. https://doi.org/10.1001/jama.292.4.490
  21. Zhang J, Fu M, Myles D, Zhu X, Du J, Cao X, Chen YE. PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways. FEBS Lett. 2002;521:180-184. https://doi.org/10.1016/S0014-5793(02)02872-7
  22. Price PA, June HH, Buckley JR, Williamson MK. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol. 2001;21:1610-1616. https://doi.org/10.1161/hq1001.097102
  23. Min H, Morony S, Sarosi I, Dunstan CR, Capparelli C, Scully S, Van G, Kaufman S, Kostenuik PJ, Lacey DL, Boyle WJ, Simonet WS. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med. 2000;192:463-474. https://doi.org/10.1084/jem.192.4.463
  24. Papadopouli AE, Klonaris CN, Theocharis SE. Role of OPG/ RANKL/RANK axis on the vasculature. Histol Histopathol. 2008;23:497-506.
  25. Davies MR, Lund RJ, Hruska KA. BMP-7 is an efficacious treatment of vascular calcification in a murine model of atherosclerosis and chronic renal failure. J Am Soc Nephrol. 2003; 14:1559-1567. https://doi.org/10.1097/01.ASN.0000068404.57780.DD
  26. Li T, Surendran K, Zawaideh MA, Mathew S, Hruska KA. Bone morphogenetic protein 7: a novel treatment for chronic renal and bone disease. Curr Opin Nephrol Hypertens. 2004;13: 417-422. https://doi.org/10.1097/01.mnh.0000133974.24935.fe
  27. Kang YH, Jin JS, Yi DW, Son SM. Bone morphogenetic protein-7 inhibits vascular calcification induced by high vitamin D in mice. Tohoku J Exp Med. 2010;221:299-307. https://doi.org/10.1620/tjem.221.299
  28. Ross R. The smooth muscle cell. II. Growth of smooth muscle in culture and formation of elastic fibers. J Cell Biol. 1971; 50:172-186. https://doi.org/10.1083/jcb.50.1.172
  29. Ha YM, Lee DH, Kim M, Kang YJ. High glucose induces connective tissue growth factor expression and extracellular matrix accumulation in rat aorta vascular smooth muscle cells via extracellular signal-regulated kinase 1/2. Korean J Physiol Pharmacol. 2013;17:307-314. https://doi.org/10.4196/kjpp.2013.17.4.307
  30. Dorai H, Vukicevic S, Sampath TK. Bone morphogenetic protein-7 (osteogenic protein-1) inhibits smooth muscle cell proliferation and stimulates the expression of markers that are characteristic of SMC phenotype in vitro. J Cell Physiol. 2000; 184:37-45. https://doi.org/10.1002/(SICI)1097-4652(200007)184:1<37::AID-JCP4>3.0.CO;2-M
  31. Murshed M, Schinke T, McKee MD, Karsenty G. Extracellular matrix mineralization is regulated locally; different roles of two gla-containing proteins. J Cell Biol. 2004;165:625-630. https://doi.org/10.1083/jcb.200402046
  32. Kawashima N, Suzuki N, Yang G, Ohi C, Okuhara S, Nakano-Kawanishi H, Suda H. Kinetics of RANKL, RANK and OPG expressions in experimentally induced rat periapical lesions. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;103: 707-711. https://doi.org/10.1016/j.tripleo.2006.11.036
  33. Corallini F, Celeghini C, Rizzardi C, Pandolfi A, Di Silvestre S, Vaccarezza M, Zauli G. Insulin down-regulates TRAIL expression in vascular smooth muscle cells both in vivo and in vitro. J Cell Physiol. 2007;212:89-95. https://doi.org/10.1002/jcp.21006
  34. Shioi A, Katagi M, Okuno Y, Mori K, Jono S, Koyama H, Nishizawa Y. Induction of bone-type alkaline phosphatase in human vascular smooth muscle cells: roles of tumor necrosis factor-alpha and oncostatin M derived from macrophages. Circ Res. 2002;91:9-16. https://doi.org/10.1161/01.RES.0000026421.61398.F2
  35. Bostrom KI. Cell differentiation in vascular calcification. Z Kardiol. 2000;89 Suppl 2:69-74. https://doi.org/10.1007/s003920070102
  36. Iyemere VP, Proudfoot D, Weissberg PL, Shanahan CM. Vascular smooth muscle cell phenotypic plasticity and the regulation of vascular calcification. J Intern Med. 2006;260: 192-210. https://doi.org/10.1111/j.1365-2796.2006.01692.x
  37. Schoppet M, Al-Fakhri N, Franke FE, Katz N, Barth PJ, Maisch B, Preissner KT, Hofbauer LC. Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Monckeberg's sclerosis and atherosclerosis. J Clin Endocrinol Metab. 2004;89:4104-4112. https://doi.org/10.1210/jc.2003-031432
  38. Al-Fakhri N, Hofbauer LC, Preissner KT, Franke FE, Schoppet M. Expression of bone-regulating factors osteoprotegerin (OPG) and receptor activator of NF-kappaB ligand (RANKL) in heterotopic vascular ossification. Thromb Haemost. 2005;94:1335-1337. https://doi.org/10.1160/TH05-06-1335
  39. Rasmussen LM, Tarnow L, Hansen TK, Parving HH, Flyvbjerg A. Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. Eur J Endocrinol. 2006;154:75-81. https://doi.org/10.1530/eje.1.02049
  40. Knudsen ST, Foss CH, Poulsen PL, Andersen NH, Mogensen CE, Rasmussen LM. Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. Eur J Endocrinol. 2003;149:39-42. https://doi.org/10.1530/eje.0.1490039
  41. Avignon A, Sultan A, Piot C, Elaerts S, Cristol JP, Dupuy AM. Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients. Diabetes Care. 2005;28:2176-2180. https://doi.org/10.2337/diacare.28.9.2176
  42. Secchiero P, Corallini F, Pandolfi A, Consoli A, Candido R, Fabris B, Celeghini C, Capitani S, Zauli G. An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction. Am J Pathol. 2006;169:2236-2244. https://doi.org/10.2353/ajpath.2006.060398
  43. Proudfoot D, Skepper JN, Hegyi L, Bennett MR, Shanahan CM, Weissberg PL. Apoptosis regulates human vascular calcification in vitro: evidence for initiation of vascular calcification by apoptotic bodies. Circ Res. 2000;87:1055-1062. https://doi.org/10.1161/01.RES.87.11.1055
  44. Hui M, Tenenbaum HC. New face of an old enzyme: alkaline phosphatase may contribute to human tissue aging by inducing tissue hardening and calcification. Anat Rec. 1998;253:91-94. https://doi.org/10.1002/(SICI)1097-0185(199806)253:3<91::AID-AR5>3.0.CO;2-H
  45. Shanahan CM, Proudfoot D, Tyson KL, Cary NR, Edmonds M, Weissberg PL. Expression of mineralisation-regulating proteins in association with human vascular calcification. Z Kardiol. 2000;89 Suppl 2:63-68. https://doi.org/10.1007/s003920050011
  46. Orita Y, Yamamoto H, Kohno N, Sugihara M, Honda H, Kawamata S, Mito S, Soe NN, Yoshizumi M. Role of osteoprotegerin in arterial calcification: development of new animal model. Arterioscler Thromb Vasc Biol. 2007;27:2058-2064. https://doi.org/10.1161/ATVBAHA.107.147868

Cited by

  1. Fibroblast growth factor 21 attenuates calcification of vascular smooth muscle cells in vitro vol.69, pp.12, 2015, https://doi.org/10.1111/jphp.12826
  2. Osteoclast-Mediated Cell Therapy as an Attempt to Treat Elastin Specific Vascular Calcification vol.26, pp.12, 2021, https://doi.org/10.3390/molecules26123643